BACE1 is a key protease controlling the formation of amyloid ␤, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academiaandindustry.Herein,wereportthenonclinicalandearlyclinicaldevelopmentofLY2886721,aBACE1activesiteinhibitorthatreached phase 2 clinical trials in AD. LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid ␤ lowering in nonclinical animal models. Similar potent and persistent amyloid ␤ lowering was observed in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects. Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.
Introduction
Alzheimer's disease (AD) is an age-related, neurodegenerative disorder characterized by progressive memory loss ultimately leading to dementia. Neuropathologic hallmarks of AD include the accumulation of extracellular amyloid plaques, intracellular neurofibrillary tangles, and neuronal loss in specific brain regions such as the hippocampus and cerebral cortex, which are important for cognition, learning, and memory. Amyloid ␤ (A␤) plaques consist primarily of assemblies of a small 39 -43 aa peptide arising from the cleavage of APP. The amyloidogenic processing of APP is initiated by BACE1 (also known as ␤-secretase), an aspartyl protease that was cloned by several groups including Sinha et al. (1999) and Vassar et al. (1999) . One of the familial forms of AD is caused by a double mutation, KM¡NL, at amino acids immediately adjacent to the BACE1 cleavage site (Mullan et al., 1992) . Kinetic assays with recombinant BACE1 demonstrate a significantly higher activity of BACE1 against this so-called Swedish mutated APP compared with wild-type residues at that site (Sinha et al., 1999; Vassar et al., 1999) , so this "gain-of-function" mutation in APP is associated with an early onset familial form of AD. Conversely, a "loss-of-function" mutation in APP has recently been described in an Icelandic kindred in which an A673T poly-morphism in APP has been associated with reduced A␤ production and apparent protection against AD and cognitive decline with aging (Jonsson et al., 2012) . These genetic data offer strong support for BACE1 as a key mediator of amyloid-driven pathology. Moreover, these findings suggest that brain penetrant BACE1 inhibitors under development may be able to delay the progression of AD by reducing the extent of amyloid formation. BACE1 knock-out (KO) mice are viable and fertile and initially were reported to be without a major phenotype (Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001) . Although more recent characterization of BACE1 KOs has revealed selected morphologic and functional deficits in these animals (for review, see Vassar et al., 2014) and has introduced a level of caution, these findings have not limited enthusiasm for the development of BACE1 inhibitors. Overall, BACE1 has represented an attractive target for the pharmaceutical industry since its original discovery (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000) . Early progress was slow due to challenges in translating potent enzymatic activity into productive BACE inhibition in central compartments in vivo. A significant breakthrough came in 2011 with the report of LY2811376, a moderately potent, drug-like BACE1 inhibitor that produced robust pharmacodynamics changes in nonclinical animal models and healthy volunteers (May et al., 2011) . Although the clinical development of this molecule was discontinued due to nonclinical, off-target-related pathology, these data provided critical support for small-molecule intervention to test the amyloid hypothesis. Herein, we describe the nonclinical and early clinical development of LY2886721, a potent BACE1 inhibitor that reached phase 2 testing in patients with AD. 5, 7, [1, 3] thiazin7a-yl)-4-fluorophenyl)-5-fluoropicolinamide (LY2886721) can be prepared as described in US Patent 8,278,411. All nonclinical studies were conducted with the hydrochloride salt of LY2886721 and all clinical studies were conducted using the free base form of LY2886721.
Materials and Methods

Preparation of LY2886721
Crystallography
BACE1 crystals were prepared as described previously with minor modifications (Hong et al., 2000) . Briefly, crystals were soaked with 2.5 mM compound and flash cooled in liquid nitrogen using glycerol as a cryoprotectant. X-ray diffraction data and BACE1 co-crystal structure was solved as described in May et al. (2011) (see Table 1 for crystallographic data).
Recombinant BACE1 and BACE2 assays
Human BACE1 and BACE2 enzyme assays were conducted essentially as described by May et al. (2011) using purified recombinant human BACE1 or BACE2 as an enzyme source and a synthetic fluorescence resonance energy transfer (FRET) peptide as a substrate.
Aspartyl protease selectivity enzyme assays
Cathepsin D, pepsin, and renin assays were conducted essentially as described by May et al. (2011) using commercially available reagents and assays. Human liver Cathepsin D was purchased from Calbiochem (catalog #219041). Porcine gastric mucosa pepsin was purchased from Sigma (catalog #P-6887). Recombinant human renin was purchased from AnaSpec (catalog #72040). For all enzyme assays, a 10-point inhibition curve was plotted and fitted with a four-parameter logistic equation to obtain the IC 50 values.
Cell-based assays
Activity of LY2886721 was evaluated in two different cell assays essentially as described in May et al. (2011) to assess potency against native BACE1 in a normal physiologic cellular membrane context. In one cellbased assay, a human embryonic kidney cell line (HEK293) stably expressing APP751cDNA containing a Swedish mutation (HEK293 Swe ) was exposed to increasing concentrations of LY2886721 and the amount of amyloid ␤ 1-40 (A␤ 1-40 ) and A␤ 1-42 measured in the media as an index of BACE1 inhibition. Compound cytotoxicity was assessed using a CellTiter96 Aqueous Non-Radioactive Cell Proliferation assay from Promega (catalog # G54530). In the second cell-based assay, primary cortical neurons prepared from embryonic day 16 PDAPP transgenic mouse embryos were exposed to increasing concentrations of LY2886721 and the amount of A␤ 1-40 and A␤ 1-42 measured in the media as an index of BACE1 inhibition. Compound cytotoxicity was assessed using the MTT cytotoxicity assay.
PDAPP mouse in vivo pharmacology
In vivo pharmacology studies were conducted in young PDAPP transgenic mice essentially as described by May et al. (2011) . Young (2-3 months old) female hemizygous APP V717F transgenic mice (PDAPP) from Taconic (private line 6042T) were used in these studies. Typically, 32-40 mice were randomly assigned by parental lineage into groups of 6 -8 mice. Studies included a control group administered a 10 ml/kg dose volume of vehicle (7% Pharmasolve) by oral gavage and drug-treated groups receiving indicated doses of LY2886721 by oral gavage. At designated time points, mice were anesthetized with CO 2 and killed by decapitation. Bilateral hippocampal and cortical brain regions were rapidly microdissected, frozen on dry ice, and stored at Ϫ80°C until analysis. The remaining brain tissue was flash frozen and used for compound exposure assessment. For analysis of parenchymal A␤, C99, and secreted amyloid precursor protein ␤ (sAPP␤), brain samples were homogenized in 5.5 M guanidine-HCl buffer and extracts were collected, diluted, and filtered before ELISA. The use of animals in these pharmacology studies conformed to the Institutional Animal Care and Use guidelines for Eli Lilly and Company.
Beagle dog in vivo pharmacology
Beagle dogs were used as a secondary in vivo pharmacology model to assess BACE1 inhibition in a nontransgenic animal model. Beagle dog pharmacology studies were conducted in a cannulated dog model established at MPI Research. In this model, beagle dogs were implanted with a cannula in the lumbar spine region and threaded up toward the cervical spine. This model allowed multiple CSF collections throughout a single 48 h study period. To assess central pharmacology of LY2886721, CSF was collected 0.5 h before dosing to establish a baseline in 6 male cannulated beagle dogs and then again at 3, 6, 9, 24, and 48 h after dosing a 1.5 mg/kg dose of LY2886721 in a standard 10% Acacia formulation by oral gavage. Blood samples were drawn at baseline and throughout the 48 h period to assess compound exposure and peripheral pharmacodynamic responses. Amyloid ␤ 1-x (A␤ 1-x ) levels were measured in CSF and plasma and averaged across all six animals, then plotted as a function of time relative to baseline. The use of animals in these pharmacology studies 
Nonclinical bioanalytical methods for LY2886721
Brain samples were weighed and a 3-fold volume of water/methanol (4:1, v/v) was added before homogenization with an ultrasonic tissue disrupter. Appropriate unlabeled internal standard was added to each brain, CSF, or plasma sample and supernatants were subjected to LC-MS/MS analysis using an Applied Biosystems/MDS Sciex API 4000 equipped with a TurboIonSpray interface and operated in positive ion mode monitoring the transition mass/charge 391¡96.
Plasma and brain protein binding
LY2886721 plasma (mouse, dog, human) and brain (mouse) protein binding was determined in vitro using equilibrium dialysis, as described previously (Zamek-Gliszczynski et al., 2011) . Unbound brain and plasma concentrations were derived by multiplying the total measured concentrations by the fraction unbound (free) determined in vitro.
Statistical methods
Statistical significance was determined by ANOVA using GraphPad Prism software (version 4). If significant, groups were compared by Dunnett's method of post hoc analysis to assess effects relative to vehicle control. Significance was set as p Յ 0.05.
Methods for clinical studies
Three randomized, placebo-controlled, subject-and investigator-blind, single-site, clinical studies were conducted to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) activity of LY2886721 after single-and multiple-dose administration. These studies were conducted in healthy male and female subjects. The clinical safety, tolerability, PK, and PD assessments after single doses of LY2886721 were derived from either 
Study design
Single-dose evaluations. In single-dose assessments, plasma PK and PD effects on A␤ 1-40 and A␤ 1-42 concentrations were evaluated after single doses of placebo or 1, 7, 15, 25, 35 (n ϭ 6/group), or 70 mg of LY2886721 (n ϭ 10). Plasma samples were obtained immediately before dosing and up to 168 h after dosing, except for 70 mg, for which plasma samples were obtained up to 96 h after dosing. For the 1 mg dose, plasma LY2886721 concentrations were generally below the limit of quantification and therefore these results are not reported. The PK and PD of LY2886721 were subsequently assessed in CSF and plasma after administration of a single doses of 10 and 35 mg of LY2886721 or placebo (n ϭ 4/group). CSF sampling was conducted as described previously (May et al., 2011) . Briefly, serial CSF samples were collected through an indwelling subarachnoid lumbar catheter from 4 h before dosing up to 36 h after dosing.
Multiple-dose evaluations. In multiple-dose assessments, subjects (n ϭ 10/group) received daily administration of study drug (5, 15, 35, or 70 mg) or placebo for 14 d. Plasma samples were obtained following the first dose for up to 24 h post dose, before the last dose (day 14) and for up to 120 h after dosing on day 14. In addition, every 2 d, plasma samples were collected before dosing to assess the time to reach steady state. CSF was sampled by a single lumbar puncture (LP) performed before dosing and again ϳ24 h after administration of the last dose of LY2886721 or placebo on day 14. At each LP, a maximum of 25 ml of CSF was collected for determination of A␤ 1-40 , A␤ 1-42 , soluble amyloid precursor protein alpha (sAPP␣), soluble amyloid precursor protein beta (sAPP␤), and LY2886721 concentrations. Any CSF sample that showed visual or laboratory evidence of blood contamination was excluded from the PK, PD, and statistical analyses.
For all studies, safety was assessed by recording adverse events (AEs), physical, neurological and ophthalmological examinations, vital signs, electrocardiograms (ECGs), and results of clinical safety laboratory tests.
Bioanalytical methods
Plasma A␤ 1-40 and A␤ 1-42 were measured simultaneously using a validated modification of the Fujirebio/Innogenetics INNO-BIA plasma amyloid-␤ (A␤) forms assay run on a Luminex xMAP platform as described previously (Lachno et al., 2012) . CSF A␤ 1-40 and A␤ 1-42 were analyzed using validated modifications of the Fujirebio/Innogenetics INNOTEST␤-AMYLOID andprototypeINNOTEST␤-AMYLOID (1-40) ELISA kits respectively as described previously (D.R. Lachno, B.A. Evert, K. Maloney, B.A. Willis, J.A. Talbot, M. Vandijck, R.A. Dean, unpublished data). CSF sAPP␣ and sAPP␤ were measured using a validated Meso Scale Discovery immunoassay as described previously (May et al., 2011) .
Clinical bioanalytical methods for LY2886721
Human plasma and CSF samples were analyzed for LY2886721 using validated liquid chromatography with tandem-mass-spectrometric detection methods by Covance Laboratories.
13 C-labeled LY2886721 was added to each sample as an internal standard. Separation was achieved using a gradient HPLC system with a Chromolith SpeedROD RP18-e column (50 ϫ 4.6 mm; Millipore) using mobile phase A (0.1% formic acid in water) and mobile phase B [0.1% formic acid in acetonitrile: methanol (50:50, v:v)]. After separation, LY2886721 was detected using a Sciex API 5000 in positive ion mode monitoring the transition mass/ charge 391¡96.
PK analysis
PK parameter estimates for LY2886721 were calculated by standard noncompartmental methods of analysis using WinNonlin Enterprise (version 5.3). Clearance and apparent volume of distribution were reported for all subjects. Time of maximum concentration (t max ) and apparent terminal half-life (t 1/2 ) were also reported. The accumulation ratio at steady state was calculated by dividing the area under the plasma concentration versus time period from time 0 to 24 h after administration (AUC (0 -24) ) at steady state by AUC (0 -24) after the initial dose for each subject.
PD analysis
For each subject with serially determined concentrations of plasma or CSF A␤ 1-40 and A␤ 1-42 , the time of the lowest observed concentration (C nadir ) was reported, along with change from baseline at C nadir and the 24 h time-averaged change from baseline after dosing. Steady-state CSF A␤ 1-40 , A␤ 1-42 , sAPP␣, and sAPP␤ concentrations were expressed as a percentage change from baseline. Summary statistics were calculated for each PD parameter.
Results
Structural characterization of LY2886721
LY2886721 is composed of a bicyclic aminothiazine core along with fluorophenyl and fluoropyridine groups, themselves connected by an amide group. An x-ray co-crystal structure of LY2886721 bound in the BACE1 active site indicates that the bicyclic aminothiazine core engages the catalytic dyad of BACE1 while the fluorophenyl ring binds in the S1 pocket (Fig. 1, Table 1 ). This molecule also appears to engage in additional interactions with the BACE1 active site compared with LY2811376, including a potential hydrogen bond between the amide N-H and a glycine residue present in the BACE1 active site and extension of the fluoropyridine group further into the S3 pocket.
BACE1 and related aspartyl protease inhibition
To determine the in vitro potency of inhibition, LY2886721 was tested against recombinant human BACE1 using a small synthetic FRET substrate (Table 2) . LY2886721 demonstrated potent inhibition with an IC 50 of 20.3 nM (SD 10.1 nM). Assessment of LY2886721 activity against hBACE2 demonstrated an IC 50 of 10.2 nM (SD 4.8 nM). BACE2 is a closely related aspartyl protease with a poorly understood function to date. Assessment of LY2886721 activity against cathepsin D, pepsin, renin, or other important aspartyl proteases showed essentially no inhibition (IC 50 Ͼ100,000 nM), suggesting that activity against these common aspartyl proteases is unlikely to be significant. Collectively, these data indicate that LY2886721 is a potent BACE1 aspartyl protease inhibitor with selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2.
Cellular assays
Two different cellular models were used to assess the in vitro cellular activity of LY2886721 (Table 2 ). The HEK293Swe model consisted of a human embryonic kidney cell stably expressing a cDNA encoding human APP harboring a Swedish mutation. Overnight exposure of HEK293Swe cells to increasing concentrations of LY2886721 showed a concentration-dependent decrease in the amount of A␤ secreted into the condition medium. Consistent with a mechanism of BACE inhibition, the EC 50 s for inhibition of A␤ 1-40 and A␤ 1-42 were essentially identical, 18.5 and 19.7 nM, respectively. These results were achieved in the absence of any overt cytotoxicity. Primary cortical neuronal cultures from embryonic PDAPP mice provided a second cellular model to assess BACE inhibition in vitro. In this assay, the APP sequence contained an Indiana mutation (APP V717F ), but the amino acid sequence around the BACE cleavage site was wild-type and, as such, was more reflective of the larger AD population. Overnight exposure of PDAPP neuronal cultures to an increasing concentration of LY2886721 produced a concentration-dependent decrease in A␤ production. As observed in HEK293Swe cells, the EC 50 s for inhibition of A␤ 1-40 and A␤ 1-42 were comparable in PDAPP neuronal cultures at ϳ10 nM.
Nonclinical characterization of LY2886721 in mice and dogs PDAPP mouse studies
The in vivo pharmacology properties of LY2886721 were initially tested in the PDAPP mouse, a transgenic mouse expressing a mini-gene for human APP harboring an APP V717F mutation (Games et al., 1995) . In an oral acute dose-response study, young PDAPP mice (n ϭ 6 -8 per group) received vehicle (7% Pharmasolve) or 3, 10, or 30 mg/kg doses of LY2886721 and were killed 3 h later. Hippocampal ( Fig. 2A) and cortical (Fig. 2B ) levels of A␤ 1-x were significantly reduced by all 3 doses of LY2886721 compared with the vehicle. These robust effects were associated with the following unbound brain exposures at 3 h after dose: 2.3, 11, and 50 nM at 3, 10, and 30 mg/kg, respectively. Consistent with an in vivo BACE1 inhibition mechanism of action, oral administration of LY2886721 resulted in significant reduction of brain parenchymal levels of C99 and sAPP␤, both primary products of BACE1 cleavage of APP. Cortical levels of C99 were significantly reduced by the 10 and 30 mg/kg doses, whereas the effect at the 3 mg/kg dose failed to reach statistical significance (Fig. 2C) . The sAPP␤ levels were significantly decreased by all three doses (Fig. 2D) . Similar results were obtained on hippocampal C99 and sAPP␤ (data not shown). Interestingly, the magnitude of the effect size for sAPP␤ was reduced relative to the effect sizes observed for A␤ 1-x and C99.
Central pharmacology studies in beagle dog
Central pharmacology studies were conducted in a cannulated beagle dog model established at MPI Research. Six male beagle dogs received 1.5 mg/kg LY2886721 in a 10% Acacia formulation orally and blood and CSF were collected over 48 h, as described previously. EDTA plasma and CSF were analyzed for A␤ 1-x by standard ELISAs. CSF samples were also evaluated for A␤ 1-40 and A␤ 1-42 .
Significant changes in plasma levels of A␤ 1-x (up to 80% reduction at the nadir) were observed at all time points after oral administration of LY2886721. CSF A␤ 1-x levels were significantly reduced at 3, 6, 9, and 24 h after oral administration of 1.5 mg/kg LY2886721 (Fig. 3) . The peak effect observed in CSF occurred at 9 h after the dose and approached an 80% reduction relative to baseline. By 48 h, CSF A␤ 1-x levels were approaching baseline values. Parallel changes of similar magnitude were observed in CSF A␤ 1-40, A␤ 1-42 , and A␤ x-40 (data not shown). The compara- Cathepsin D FRET assay (n ϭ 1/6): Ͼ300,000 Pepsin FRET assay (n ϭ 5): Ͼ100,000
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PDAPP 1 o neuron A␤ 1-40 (n ϭ 6): 10.7 (3.5) PDAPP 1 o neuron A␤ 1-42 (n ϭ 6): 9.2 (3.9) PDAPP 1 o neuron cytotox (n ϭ 1/6): Ͼ50,000 hBACE1, human recombinant beta-APP cleaving enzyme1; hBACE2, human recombinant beta-APP cleaving enzyme 2; IC 50 , concentration at which enzyme activity is inhibited by 50%; mca, methylcoumarin. ble changes in all A␤ isoforms are consistent with the inhibition of the BACE1 protease. These prominent PD effects were associated with peripheral exposures averaging an unbound drug AUC of 1383 Ϯ 754 nM/h (mean Ϯ SD; n ϭ 6) and a free drug maximum concentration (C max ) at 1 h after dose of 118 Ϯ 32 nM (mean Ϯ SD; n ϭ 6). The total drug exposure in CSF averaged 1222 Ϯ 730 nM/h (mean Ϯ SD; n ϭ 6), which is comparable to the free unbound exposure of drug in plasma, suggesting excellent brain permeability for LY2886721.
Hippocampus Aβ
Clinical characterization of LY2886721 in healthy volunteers
A total of 95 subjects were enrolled in all 3 studies. Subject characteristics for each study are shown in Table 3 .
PK
Single-dose plasma concentrations of LY2886721 were generally not quantifiable after the 1 mg of dose, so no PK parameters were estimated at this dose level. After single doses of 5-70 mg of LY2886721, the plasma concentrations rose, reaching a maximum concentration at a median of 3 h after dose (range 1-8 h), and then fell in a multiexponential manner. The geometric mean terminal elimination t 1/2 was determined to be 17.2 h (range 8.19 -36.3 h). The PK appeared to be linear with respect to dose; the geometric mean apparent oral clearance was 34.8 L/h (38% CV) and the apparent volume of distribution during the terminal phase was 863 L (56% CV) across dose levels. The PK of LY2886721 was consistent between studies.
Serial CSF sampling was conducted at doses of 10 and 35 mg. Maximum concentration of LY2886721 in CSF were reached at ϳ5 h after dosing (range 3-6 h). The mean AUC (0 -ϱ) in CSF was 18.4% (10 mg dose) to 15.1% (35 mg dose) of the total AUC (0 -ϱ) observed in plasma (data not shown). At 24 h after a 70 mg dose, the geometric mean (%CV) CSF concentration was 6.71 ng/ml (31%). On average, these concentrations were 18.6% of the total concentration measured in plasma when measured at the same time (range 12.8 -22.8%).
In the multiple-dose evaluations, steady state was achieved ϳ4 -8 d after the start of daily dosing. At steady state across doses, the median t max was 4 h after dose (range 1-8 h). The mean terminal t 1/2 estimates value was 23.2 h (36.1% CV). Clearance at steady state was similar to that observed after single doses, with an overall mean value of 35.4 L/h (32.7% CV). After repeated daily doses, some accumulation of LY2886721 was observed. Across dose groups, the mean accumulation ratio (RA) was 1.43 (26.5% CV).
PD
Single-dose plasma A␤ PD. After single doses of LY2886721, plasma A␤ 1-40 and A␤ 1-42 concentrations decreased significantly, reached a nadir, and then slowly returned to predose baseline values (Fig. 4) . The time at which the nadir occurred ranged from a mean of 6 to 12 h and appeared to be independent of dose. The Peripheral and central PD effects of LY2886721 in beagle dogs after a single 1.5 mg/kg dose. Baseline plasma and CSF samples were collected from cannulated beagle dogs (n ϭ 6) before dosing with 1.5 mg/kg LY2886721. After dosing, plasma and CSF samples were collected at various times and stored for analysis; A␤ 1-x levels are measured in plasma and CSF and averaged across all 6 animals. Baseline plasma A␤ 1-x was 234 Ϯ 17 pg/ml (mean Ϯ SEM; n ϭ 6) and baseline CSF A␤ 1-x was 4.85 Ϯ 0.64 ng/ml (mean Ϯ SEM; n ϭ 6). LY2886721 produced robust and time-dependent decreases in A␤ 1-x in both plasma and CSF of dog relative to baseline. **p Ͻ 0.01 compared with baseline. p-values derived from ANOVA: Dunnett's post hoc analysis. *n represents those subjects of a total of 30 enrolled in Study 3 who received doses of 70 mg of LY2886721 or placebo; 10 subjects received at least a single dose of LY2886721 and 5 subjects had placebo.
magnitude of the decrease in plasma A␤ 1-40 and A␤ 1-42 , as measured either by the nadir or the average reduction over the first 24 h, tended to increase with increasing doses of LY2886721. For the 70 mg dose, the change from baseline at nadir in A␤ 1-40 and A␤ 1-42 was Ϫ83.3 Ϯ 4.74% and Ϫ74.0 Ϯ 6.80%, respectively.
Single-dose CSF A␤ PD.
A single 35 mg dose of LY2886721 decreased A␤ 1-40 and A␤ 1-42 concentrations in serially collected CSF specimens. This effect was first apparent ϳ4 h after dosing. The time to reach nadir concentrations varied widely between subjects, with median times of ϳ17 h after dose administration. , 7, 10, 15, 25, 35 , and 70 mg of LY2886721 in healthy subjects. Subjects received a single dose of 5, 7, 10, 15, 25, 35, or 70 mg of LY2886721 (n ϭ at least 6/dose) or placebo. Samples were drawn for PD biomarkers at baseline and at times up to 168 h after dosing. The time at which the mean nadir occurred across LY2886721 doses was 6 -12 h and appeared to be independent of dose. The reduction from baseline in levels of A␤ species, as measured by either the nadir or the average reduction over the first 24 h, tended to increase with increasing doses of LY2886721. At the highest dose, 70 mg, the reduction from baseline was 83.3% for plasma concentrations of A␤ 1-40 (A) and 74.0% for A␤ 1-42 (B) . Plasma levels of A␤ 1-40 and A␤ 1-42 slowly approached baseline levels by 168 h.
Although the CSF A␤ 1-40 and A␤ 1-42 change from baseline after the single 35 mg doses of LY2886721 was qualitatively similar for both isoforms, the percentage change for A␤ 1-40 was slightly greater than for A␤ , as shown in Figure 5 . Multiple-dose plasma A␤ PD. After 14 d of daily dosing, administration of 5-70 mg of LY2886721 dose-dependently decreased concentrations of A␤ 1-40 and A␤ 1-42 in plasma serially collected after the last dose. The observed percentage decreases in plasma A␤ 1-40 relative to baseline were quantitatively greater than that observed for plasma A␤ 1-42 . The median time at which a nadir was reached for the 2 A␤ isoforms after the final daily dose of 35 and 70 mg of LY2886721 was 6 -10 h (Fig. 6) .
Multiple-dose CSF A␤ PD. After 14 d of daily dosing, administration of placebo or increasing doses of LY2886721 revealed dose-dependent decreased concentrations of A␤ 1-40 and A␤ in CSF collected ϳ24 h after the last dose. The mean (ϮSD) A␤ 1-40 percentage change from baseline for placebo, 5, 15, 35, and 70 mg was Ϫ0.58% (Ϯ8.67), Ϫ17.7% (Ϯ4.99), Ϫ29.1% (Ϯ7.15), Ϫ57.6% (Ϯ5.00), and Ϫ74.4% (Ϯ1.68), respectively (Fig. 7) . The mean (ϮSD) A␤ 1-42 percentage change from baseline for placebo, 5, 15, 35, and 70 mg was Ϫ4.96% (Ϯ8.34), Ϫ20.1% (Ϯ1.26), Ϫ30.0% (Ϯ10.4), Ϫ53.2% (Ϯ3.95), and Ϫ71.3% (Ϯ1.59), respectively (Fig. 7) .
Multiple-dose CSF sAPP␣ and sAPP␤ PD. To examine LY2886721 target engagement and the indirect and direct impact of BACE inhibition on APP processing, concentrations of CSF sAPP␣ and sAPP␤ were measured after repeated daily dosing for 14 d. CSF was collected before and ϳ24 h after the final day 14 administration of placebo or one of the LY2886721 treatments. There was a clear dose-response relationship from placebo to 70 mg daily dosing for the mean change from baseline in CSF measurements of sAPP␣ and sAPP␤. The mean (ϮSD) CSF sAPP␤ decreases from baseline at 24 h for placebo, 5, 15, 35, and 70 mg were 7.75% (Ϯ15.8), 22.1% (Ϯ17.0), 35.8% (Ϯ6.50), 59.0% (Ϯ5.47), and 77.4% (Ϯ3.11), respectively. The mean (SD) CSF sAPP␣ increases from baseline at 24 h for placebo, 5, 15, 35, and 70 mg were Ϫ5.56% (Ϯ10.3), 7.74% (Ϯ14.1), 48.2% (Ϯ12.3), 74.4% (Ϯ9.02), and 59.1% (Ϯ22.7) (Fig. 7) .
Safety
Overall, there were no serious AEs reported for LY2886721 administered up to 70 mg as single or multiple doses. In addition, no subject withdrew from the study because of an AE. Two subjects experienced transient elevations in liver function enzymes. Both were asymptomatic and occurred without bilirubin elevation. One subject experienced elevated serum aspartate aminotransferase (AST, peak 3ϫ ULN) and alanine aminotransferase [ALT, peak 4ϫ upper limit of normal (ULN)], after a single dose of 35 mg of LY2886721, which returned to baseline 2 weeks after dosing. The other subject experienced transient mild elevations in AST (peak 1.9ϫ ULN 5 d after dose) and ALT (peak 3.3ϫ ULN peak 5 d after dose) following a single dose of 70 mg of LY2886721, which returned to ULN within 2 months after discontinuation of the study drug. The most common AEs after single-dose administration of LY2886721 were dizziness and headache. The most common AEs after multiple-dose administration of LY2886721 were procedural headache (n ϭ 2) and 1 occurrence each of headache, visual field test abnormality, orthostatic hypotension, libido decrease, sinus congestion, chest pain, oral herpes, viral infection, muscle spasm, cough, insomnia, and rash (Table 4) . AEs were generally mild to moderate in severity. The most common AEs associated with CSF collection were a postprocedural headache and puncture site pain. There were no clinically significant findings in vital signs, ECGs (including QTc interval), neurological, or ophthalmological examinations. Clin- ical laboratory tests were unremarkable aside from transiently elevated liver enzyme activities described previously.
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Discussion
BACE1 is positioned at the very top of the amyloid cascade hypothesis by virtue of its initiating role in the production of A␤ peptide. Following a significant lag time after the cloning of BACE1 in 1999 (Vassar et al., 1999; Sinha et al., 1999) 5 mg (n ϭ 10) 15 mg (n ϭ 10) 35 mg (n ϭ 9) 70 mg (n ϭ 6) All doses (n ϭ 35)
Adverse event, all-cause and related to study drug, by treatment, in order of frequency. Rel, Related to study drug; Tot, total; URI, upper respiratory tract infection. *Only this adverse event was moderate in severity and all others were mild in severity. None was considered severe.
molecule was halted after the discovery of retinal epithelial pathology in nonclinical toxicology studies (May et al., 2011) . Herein, we report the nonclinical and phase 1 clinical data for LY2886721, a potent small-molecule, active-site inhibitor of BACE1. Compared with LY2811376, LY2886721 demonstrates 10-fold more potent inhibition of BACE1 and significantly reduced potency against cathepsin D, a key off-target protease. Reduced potency also was observed against pepsin and renin, thereby resulting in substantially increased protease selectivity compared with LY2811376 (May et al., 2011) . The intrinsic potency of LY2886721 against purified recombinant enzyme is maintained in two cell-based assays indicating good access to BACE1 expressed in its normal cellular compartments. Moreover, LY2886721 produced robust dose-dependent reductions in hippocampal and cortical A␤, C99, and sAPP␤ levels after oral dosing in a PDAPP transgenic mouse model. This constellation of changes in APP-processing catabolites is consistent with a mechanism of BACE1 inhibition in vivo. Finally, in a cannulated beagle dog model that permits continuous sampling of CSF, oral administration of 1.5 mg/kg LY2886721 produced significant and persistent A␤ lowering in CSF. CSF concentrations of LY2886721 in this study approximated free plasma concentrations, suggesting that the increase in BACE1 potency displayed by LY2886721 relative to LY2811376 was achieved without compromising CNS penetration. This robust pharmacology, coupled with a nonclinical toxicology profile without adverse retinal epithelial pathology at pharmacologic doses (as seen previously with LY2811376), led to the advancement of LY2886721 into early phase clinical trials.
Accordingly, a series of single ascending dose (SAD) and multiple ascending dose (MAD) studies were conducted in healthy subjects with LY2886721. In SAD studies, a robust PK/PD relationship was observed after single doses of LY2886721, as evidenced by dose-dependent, statistically significant reductions in plasma A␤ 1-40 and A␤ 1-42 that correlated well with free drug concentrations in plasma. Similarly, a single 35 mg dose of LY2886721 produced a robust (40% relative to baseline) and sustained (nadir at 18 h after dosing) reduction in CSF A␤ 1-40 and A␤ . As in the cannulated dog study, CSF concentrations of LY2886721 approximated free drug concentrations in plasma, providing further evidence that LY2886721 is freely permeable across the blood-brain barrier. In MAD studies in which repeated doses of LY2886721 were administered over 14 d, plasma PD responses observed on the last day of dosing were moderately greater than those in the SAD studies at comparable doses, consistent with the higher plasma concentrations of LY2886721 at steady state compared with that after a single dose. For a similar reason, there was a larger PD response in lumbar CSF sampled 24 h after the last of 14 d of dosing compared with PD evaluations in CSF during single-dose studies. Consistent with BACE1 inhibition in vivo, there were comparable dose-dependent reductions in CSF sAPP␤, the proximal cleavage product of BACE1 on APP, and largely concomitant opposite effects on CSF sAPP␣, suggestive of enhanced nonamyloidogenic processing of APP with BACE1 inhibition.
These robust PD effects were obtained in the absence of significant AEs. No clinically significant findings were reported for LY2886721 across the three clinical studies apart from transiently elevated liver enzymes in two subjects. Collectively, these data suggest that LY2886721 can be administered to humans at doses demonstrating significant target engagement for up to 2 weeks without significant AEs.
Based in part on the results described herein, a phase 2 study was conducted to examine the safety, tolerability, and PD effects of LY2886721 in patients with mild cognitive impairment due to AD or mild AD (www.ClinicalTrials.gov identifier NCT01561430). During the course of the study, routine safety monitoring detected abnormal liver enzyme elevations in 4 patients of 70 (unpublished data) and, therefore, Lilly chose to terminate the study. Although 2 subjects exhibited elevated ALT and AST in the phase 1 studies reported herein, there was no dose dependency in severity or incidence observed, so the relationship to LY2886721 for the abnormal liver enzyme elevations in the phase 1 studies is unclear.
Several other BACE1 inhibitors have advanced to human clinical trials (Yan and Vassar, 2014) and the clinical safety of longterm BACE1 inhibition remains to be established. The initial impression of a relatively benign phenotype for the original BACE1 KO (Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001) has been eroded the last few years by a steady stream of new phenotypic abnormalities, including hypomyelination (Hu et al., 2006; Willem et al., 2006) , axon guidance defects (Rajapaksha et al., 2011; Cao et al., 2012 , Hitt et al., 2012 , and muscle spindle reduction (Cheret et al., 2013) , as reviewed in Yan and Vassar (2014) . Many of these are judged to be more developmental processes and linked to a complete KO of BACE1 and whether partial inhibition of BACE1 in elderly patients would elicit similar changes is not clear. Nonetheless, these observations in BACE1 KO mice provide guidance for monitoring potential AEs in longterm clinical trials for BACE1 inhibitors in AD.
Many, if not all, of the current BACE1 inhibitors in development are thought to be relatively nonselective for BACE1 versus BACE2. The high homology of the active sites of BACE1 and BACE2 makes designing selectivity for BACE1 a considerable challenge. This challenge to medicinal chemists has been heightened recently by the emergence of studies describing functions for BACE2. In particular, mice with a genetic KO of BACE2 express a silver hair color instead of black and this phenotype has been ascribed to altered processing of pigment-cell-specific melanocyte protein, a newly discovered BACE2 substrate (Rochin et al., 2013) . Transmembrane protein 27 (TMEM27) is another newly discovered BACE2 substrate that is highly expressed in the pancreas (Esterházy et al., 2011) and has been suggested to play a role in supporting pancreatic ␤-cell mass. As with BACE1, other substrates for BACE2 may emerge, but for now, the functional implication for the lack of selectivity against BACE1 and BACE2, other than a potential risk of hypopigmentation, is something the field is carrying forward.
Since its initial cloning in 1999, BACE1 has been a prime drug discovery target for industry and academia. Overcoming a myriad of challenges in "drugging," this target had delayed development of potent BACE1 inhibitors, but several BACE1 inhibitors have now progressed into the clinical setting. Despite the setbacks from unanticipated nonclinical toxicology and clinical AEs experienced with LY2811376 and LY2886721, respectively, which led to the eventual termination of these molecules, the promise of BACE1 inhibitors to test the amyloid hypothesis remains strong. As the field moves toward earlier treatment of individuals with preclinical disease, targeting a protease such as BACE1, which resides at the top of the amyloid cascade, remains a compelling approach. Supporting genetic data from rare mutations in APP that alter BACE1 processing, as exemplified by the A673T APP polymorphism (Jonsson et al., 2012) , suggest that relatively modest but sustained inhibition of BACE1 could be an effective strategy for delaying disease progression. The field eagerly awaits this ultimate test of the amyloid hypothesis.
